These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10869411)

  • 1. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.
    Millan MJ; Dekeyne A; Rivet JM; Dubuffet T; Lavielle G; Brocco M
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1063-73. PubMed ID: 10869411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors.
    Millan MJ; Girardon S; Monneyron S; Dekeyne A
    Neuropharmacology; 2000 Feb; 39(4):586-98. PubMed ID: 10728880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.
    Millan MJ; Seguin L; Gobert A; Cussac D; Brocco M
    Psychopharmacology (Berl); 2004 Jul; 174(3):341-57. PubMed ID: 14985929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The involvement of cerebellar dopamine D3 receptors in locomotor activity of rats.
    Kolasiewicz W; Maj J; Ossowska K
    J Neural Transm (Vienna); 2008 May; 115(5):677-81. PubMed ID: 18188494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
    Yarkov AV; Hanger D; Reploge M; Joyce JN
    Pharmacol Biochem Behav; 2003 Dec; 76(3-4):551-62. PubMed ID: 14643855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors.
    Cussac D; Newman-Tancredi A; Sezgin L; Millan MJ
    Eur J Pharmacol; 2000 Apr; 394(1):47-50. PubMed ID: 10771033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.
    Watson DJ; Loiseau F; Ingallinesi M; Millan MJ; Marsden CA; Fone KC
    Neuropsychopharmacology; 2012 Feb; 37(3):770-86. PubMed ID: 22030711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
    Dekeyne A; Rivet JM; Gobert A; Millan MJ
    Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
    Brocco M; Dekeyne A; Papp M; Millan MJ
    Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110.
    Park WK; Jeong D; Yun CW; Lee S; Cho H; Kim GD; Koh HY; Pae AN; Cho YS; Choi KI; Jung JY; Jung SH; Kong JY
    Pharmacol Res; 2003 Dec; 48(6):615-22. PubMed ID: 14527827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
    Etievant A; Bétry C; Arnt J; Haddjeri N
    Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011.
    Gyertyán I; Sághy K
    Behav Pharmacol; 2004 Jul; 15(4):253-62. PubMed ID: 15252275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
    Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of selective dopamine D1- and D2-type receptor antagonists on the development of behavioral sensitization to 7-OH-DPAT.
    Mattingly BA; Himmler C; Bonta T; Rice LL
    Psychopharmacology (Berl); 1998 Dec; 140(4):387-97. PubMed ID: 9888612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.